AstraZeneca has had a setback in its late-stage oncology pipeline, after AKT inhibitor ceralasertib, given in combination with cancer immunotherapy Imfinzi, failed to extend survival in a lung cancer ...
Through its annual awards program, AFCEA International recognizes the outstanding contributions of individuals in the communications, electronics, intelligence and information technology disciplines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback